Latest in Lipid Treatment Guidelines and Challenges

Learn current strategies for managing high-risk dyslipidemia including the use of PCSK9 Inhibitors. Case studies in familial hyperlipidemia demonstrate the application of lipid-lowering therapies in practice.

Lipid Management
Member Cost: $0Non-member Cost: $0
Credits: 1.0 CE contact hours, 0.5 CE pharmacology hours

Course Overview

Register

Improve Access to New LDL-C Therapies

Learn current strategies for managing high-risk dyslipidemia including the use of PCSK9 Inhibitors. Case studies in familial hyperlipidemia demonstrate the application of lipid-lowering therapies in practice.

Learning Objectives

Upon completion of this continuing education course, participants will be able to:

  • Compare available pharmacotherapies used to treat elevated LDL-C in high-risk patients.
  • Discuss the details of recent outcomes trials of PCSK9 inhibitors including value-related data.
  • Identify the current dyslipidemia guidelines and consensus statements to achieve LDL-C goal.
  • Provide professional- and patient-related strategies to improve patients access to new cardiovascular disease therapies.
  • Illustrate, using case studies, treatment plans for LDL-C reduction in patients with familial hyperlipidemia and atherosclerotic cardiovascular disease.

Supported by an independent educational grant from Sanofi/Regeneron.

Faculty

  • Kathleen Byrne MSN, CRNP